This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Infectious Diseases, Other  • Corneal Disorders  • Endophthalmitis  • Drug Therapy  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

G. Atma Vemulakonda, MD; Seenu M. Hariprasad, MD; William F. Mieler, MD; Randall A. Prince, PharmD; Gaurav K. Shah, MD; Russell N. Van Gelder, MD, PhD

Arch Ophthalmol. 2008;126(1):18-22.

Objective  To determine the penetration of 1% voriconazole solution into the aqueous and vitreous following topical administration.

Methods  A prospective nonrandomized study of 13 patients scheduled for pars plana vitrectomy surgery. Aqueous and vitreous samples were obtained and analyzed after topical administration of 1% voriconazole every 2 hours for 24 hours before surgery. Drug concentration quantitation was performed using high-performance liquid chromatography.

Results  The mean (SD) sampling time after topical administration of the last voriconazole dose was 24 (14) minutes. The mean (SD) voriconazole concentrations in the aqueous and vitreous were 6.49 (3.04) µg/mL and 0.16 (0.08) µg/mL, respectively. Aqueous concentrations exceeded the minimum inhibitory concentration at which 90% of isolates are inhibited (MIC₉₀) for a wide spectrum of fungi and mold, including Aspergillus, Fusarium, and Candida species. Vitreous concentrations of voriconazole exceeded the MIC₉₀ for Candida albicans.

Conclusion  Topically administered voriconazole achieves therapeutic concentrations in the aqueous of the noninflamed human eye for many fungi and molds and achieves therapeutic levels in the vitreous for Candida species. Topical voriconazole may be a useful agent for the management of fungal keratitis and for prophylaxis against the development of fungal endophthalmitis.

Author Affiliations: Departments of Ophthalmology and Visual Sciences (Drs Vemulakonda, Shah, and Van Gelder) and Molecular Biology and Pharmacology (Dr Van Gelder), Washington University School of Medicine, and Barnes Retina Institute (Drs Hariprasad, Shah, and Van Gelder), St Louis, Missouri; Department of Ophthalmology and Visual Science, The University of Chicago, Chicago, Illinois (Dr Mieler); and College of Pharmacy, University of Houston, Houston, Texas (Dr Prince). Dr Vemulakonda is now with the Retina Division, Casey Eye Institute, Oregon Health and Science University, Portland. Dr Hariprasad is now with the Department of Ophthalmology and Visual Science, The University of Chicago. Dr Van Gelder is now with the Department of Ophthalmology, University of Washington Medical School, Seattle.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Stability of extemporaneously prepared voriconazole ophthalmic solution
Al-Badriyeh et al.
Am J Health Syst Pharm 2009;66:1478-1483.
ABSTRACT | FULL TEXT  

Prospective Open-Label Study of the Administration of Two-Percent Voriconazole Eye Drops
Al-Badriyeh et al.
Antimicrob. Agents Chemother. 2009;53:3153-3155.
ABSTRACT | FULL TEXT  

Pharmacokinetics of Intracameral Voriconazole Injection
Shen et al.
Antimicrob. Agents Chemother. 2009;53:2156-2157.
ABSTRACT | FULL TEXT  

Voriconazole in the treatment of fungal eye infections: a review of current literature
Hariprasad et al.
Br J Ophthalmol 2008;92:871-878.
ABSTRACT | FULL TEXT